Therefore, we may speculate the AP-1 complexes' selective depletion can reinforce the responses of effective anti-tumor T-cells and amplify the efficacy of immunotherapy by removing the immune inhibition and damaging the immunosuppressive functions of Tregs. The gene discussed is JUND; the disease is neoplasm.